1. Home
  2. FAF vs BBIO Comparison

FAF vs BBIO Comparison

Compare FAF & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FAF
  • BBIO
  • Stock Information
  • Founded
  • FAF 1889
  • BBIO 2015
  • Country
  • FAF United States
  • BBIO United States
  • Employees
  • FAF N/A
  • BBIO N/A
  • Industry
  • FAF Specialty Insurers
  • BBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • FAF Finance
  • BBIO Health Care
  • Exchange
  • FAF Nasdaq
  • BBIO Nasdaq
  • Market Cap
  • FAF 6.7B
  • BBIO 6.7B
  • IPO Year
  • FAF N/A
  • BBIO 2019
  • Fundamental
  • Price
  • FAF $66.49
  • BBIO $33.02
  • Analyst Decision
  • FAF Buy
  • BBIO Strong Buy
  • Analyst Count
  • FAF 4
  • BBIO 12
  • Target Price
  • FAF $74.50
  • BBIO $52.64
  • AVG Volume (30 Days)
  • FAF 786.6K
  • BBIO 2.7M
  • Earning Date
  • FAF 04-23-2025
  • BBIO 05-01-2025
  • Dividend Yield
  • FAF 3.25%
  • BBIO N/A
  • EPS Growth
  • FAF N/A
  • BBIO N/A
  • EPS
  • FAF 1.26
  • BBIO N/A
  • Revenue
  • FAF $6,128,100,000.00
  • BBIO $221,902,000.00
  • Revenue This Year
  • FAF $16.46
  • BBIO $12.42
  • Revenue Next Year
  • FAF $10.16
  • BBIO $123.19
  • P/E Ratio
  • FAF $52.09
  • BBIO N/A
  • Revenue Growth
  • FAF 2.08
  • BBIO 2285.27
  • 52 Week Low
  • FAF $51.60
  • BBIO $21.62
  • 52 Week High
  • FAF $70.92
  • BBIO $39.47
  • Technical
  • Relative Strength Index (RSI)
  • FAF 60.05
  • BBIO 45.09
  • Support Level
  • FAF $65.09
  • BBIO $35.77
  • Resistance Level
  • FAF $66.68
  • BBIO $37.06
  • Average True Range (ATR)
  • FAF 1.10
  • BBIO 1.46
  • MACD
  • FAF 0.14
  • BBIO -0.01
  • Stochastic Oscillator
  • FAF 89.63
  • BBIO 23.60

About FAF First American Corporation (New)

First American Financial Corp is a financial services business providing insurance through segments: Title insurance and related services segment include real estate insurance, property closing services, third-party handling of real estate funds (escrow), risk mitigation, real estate data products, and related real estate transaction services; The home warranty segment provides residential service contracts that cover residential systems, such as heating and air conditioning systems, and certain appliances against failures that occur as the result of normal usage during the coverage period; and The corporate segment includes investments in venture-stage companies, certain financing facilities and corporate services supporting the company's business operations.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: